HMH. Miyake
H. Miyake
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
H. Miyake has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
M Fujisawa
Division of Urology, Kobe University Graduate school of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
1 shared publicationM. E. Gleave
Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, Canada
1 shared publicationM. Fujisawa
Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
1 shared publication- Martin Gleave
University of British Columbia 11 Department of Urologic Sciences Vancouver, Canada
1 shared publication Y Kususda
Division of Urology, Kobe University Graduate School of medicine, Chuo-ku, Japan
1 shared publicationY. Kususda
Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
1 shared publication
Latest Publications
- Open Access
- 3 December 2024
- Published by Springer Nature in British Journal of Cancer
- Vol. 132 (1) , 138
Editorial Expression of Concern: Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
- 3 December 2024
- Published by Springer Nature in British Journal of Cancer
- Vol. 132 (1) , 138
Open AccessEditorial Expression of Concern: Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
- Open Access
- 15 May 2012
- Published by Springer Nature in British Journal of Cancer
- Vol. 106 (12) , 1945-1952
Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
Background: Methods: Results: Conclusion:
- 15 May 2012
- Published by Springer Nature in British Journal of Cancer
- Vol. 106 (12) , 1945-1952
Open AccessClusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
Background: Methods: Results: Conclusion: